In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (NASDAQ:ARNA) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (NASDAQ:VVUS) Qsymia could impact the stock in the coming weeks.
Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.